Skandinaviska Enskilda Banken (SEB)
FDMT icon

Skandinaviska Enskilda Banken (SEB)’s 4D Molecular Therapeutics FDMT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-44,600
Closed -$482K – 850
2024
Q3 		$482K Hold
44,600
– – ﹤0.01% 716
2024
Q2 		$936K Hold
44,600
– – ﹤0.01% 647
2024
Q1 		$1.42M Buy
+44,600
New +$1.14M 0.01% 627

Other funds holding FDMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s FDMT Position: Q4 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 44,600 shares — an estimated $482K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in FDMT in Q1 2024 and held it in 3 quarters. The position peaked at $1.42M in Q1 2024. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 44,600 4D Molecular Therapeutics shares in Q4 2024, an estimated $482K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s 4D Molecular Therapeutics position peaked at $1.42M in Q1 2024.
  • 145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2024, filed 10 Feb 2025.